Income Statement
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $5.2M | — | +14.2% |
| SG&A Expense | $2.3M | — | -5.7% |
| Interest Expense | $28K | — | — |
| Net Income | -$7.5M | — | -13.1% |
| EPS (Basic) | -$0.13 | — | +13.3% |
| EPS (Diluted) | -$0.13 | — | +13.3% |
Balance Sheet
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.3M | +74.0% | +1.3% |
| Current Assets | $7.0M | +51.1% | -51.3% |
| Total Assets | $29.7M | +8.6% | +102.9% |
| Current Liabilities | $6.1M | +2.5% | +26.9% |
| Total Liabilities | $6.5M | +1.5% | +36.2% |
| Stockholders' Equity | $23.2M | +10.8% | +135.3% |
Cash Flow
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.4M | — | +6.9% |
| Capital Expenditures | $49K | — | +14.5% |
| Investing Cash Flow | -$49K | — | +95.8% |
| Financing Cash Flow | $7.1M | — | +1403.2% |
| Free Cash Flow | -$4.5M | — | +6.7% |